PLGA Nanoparticles for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Novel Approach towards Reduction of Renal Radiation Dose
Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation expos...
Saved in:
| Published in | PloS one Vol. 7; no. 3; p. e34019 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
Public Library of Science
19.03.2012
Public Library of Science (PLoS) |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a nanocarrier to deliver PRRT drugs specifically to the tumor can reduce the associated nephrotoxicity. Based on this, (177)Lu-DOTATATE loaded PLGA nanoparticles (NPs) were formulated in the present study, as a potential therapeutic model for NETs.
DOTATATE was labeled with Lutetium-177 ((177)Lu) (labeling efficiency 98%; R(f)∼0.8). Polyethylene Glycol (PEG) coated (177)Lu-DOTATATE-PLGA NPs (50:50 and 75:25) formulated, were spherical with mean size of 304.5±80.8 and 733.4±101.3 nm (uncoated) and 303.8±67.2 and 494.3±71.8 nm (coated) for PLGA(50:50) and PLGA(75:25) respectively. Encapsulation efficiency (EE) and In-vitro release kinetics for uncoated and coated NPs of PLGA (50:50 & 75:25) were assessed and compared. Mean EE was 77.375±4.98% & 67.885±5.12% (uncoated) and 65.385±5.67% & 58.495±5.35% (coated). NPs showed initial burst release between 16.64-21.65% with total 42.83-44.79% over 21 days. The release increased with coating to 20.4-23.95% initially and 60.97-69.12% over 21 days. In-vivo studies were done in rats injected with (177)Lu-DOTATATE and (177)Lu-DOTATATE-NP (uncoated and PEG-coated) by imaging and organ counting after sacrificing rats at different time points over 24 hr post-injection. With (177)Lu-DOTATATE, renal uptake of 37.89±10.2%ID/g was observed, which reduced to 4.6±1.97% and 5.27±1.66%ID/g with uncoated and coated (177)Lu-DOTATATE-NP. The high liver uptake with uncoated (177)Lu-DOTATATE-NP (13.68±3.08% ID/g), reduced to 7.20±2.04%ID/g (p = 0.02) with PEG coating.
PLGA NPs were easily formulated and modified for desired release properties. PLGA 50:50 NPs were a more suitable delivery vehicle for (177)Lu-DOTATATE than PLGA 75:25 because of higher EE and slower release rate. Reduced renal retention of (177)Lu-DOTATATE and reduced opsonisation strongly advocate the potential of (177)Lu-DOTATATE-PLGA-PEG NPs to reduce radiation dose in PRRT. |
|---|---|
| AbstractList | Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a nanocarrier to deliver PRRT drugs specifically to the tumor can reduce the associated nephrotoxicity. Based on this, .sup.177 Lu-DOTATATE loaded PLGA nanoparticles (NPs) were formulated in the present study, as a potential therapeutic model for NETs. DOTATATE was labeled with Lutetium-177 (.sup.177 Lu) (labeling efficiency 98%; R.sub.f ~0.8). Polyethylene Glycol (PEG) coated .sup.177 Lu-DOTATATE-PLGA NPs (50:50 and 75:25) formulated, were spherical with mean size of 304.5±80.8 and 733.4±101.3 nm (uncoated) and 303.8±67.2 and 494.3±71.8 nm (coated) for PLGA(50:50) and PLGA(75:25) respectively. Encapsulation efficiency (EE) and In-vitro release kinetics for uncoated and coated NPs of PLGA (50:50 & 75:25) were assessed and compared. Mean EE was 77.375±4.98% & 67.885±5.12% (uncoated) and 65.385±5.67% & 58.495±5.35% (coated). NPs showed initial burst release between 16.64-21.65% with total 42.83-44.79% over 21days. The release increased with coating to 20.4-23.95% initially and 60.97-69.12% over 21days. In-vivo studies were done in rats injected with .sup.177 Lu-DOTATATE and .sup.177 Lu-DOTATATE-NP (uncoated and PEG-coated) by imaging and organ counting after sacrificing rats at different time points over 24 hr post-injection. With .sup.177 Lu-DOTATATE, renal uptake of 37.89±10.2%ID/g was observed, which reduced to 4.6±1.97% and 5.27±1.66%ID/g with uncoated and coated .sup.177 Lu-DOTATATE-NP. The high liver uptake with uncoated .sup.177 Lu-DOTATATE-NP (13.68±3.08% ID/g), reduced to 7.20±2.04%ID/g (p = 0.02) with PEG coating. PLGA NPs were easily formulated and modified for desired release properties. PLGA 50:50 NPs were a more suitable delivery vehicle for .sup.177 Lu-DOTATATE than PLGA 75:25 because of higher EE and slower release rate. Reduced renal retention of .sup.177 Lu-DOTATATE and reduced opsonisation strongly advocate the potential of .sup.177 Lu-DOTATATE-PLGA-PEG NPs to reduce radiation dose in PRRT. Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a nanocarrier to deliver PRRT drugs specifically to the tumor can reduce the associated nephrotoxicity. Based on this, (177)Lu-DOTATATE loaded PLGA nanoparticles (NPs) were formulated in the present study, as a potential therapeutic model for NETs. DOTATATE was labeled with Lutetium-177 ((177)Lu) (labeling efficiency 98%; R(f)∼0.8). Polyethylene Glycol (PEG) coated (177)Lu-DOTATATE-PLGA NPs (50:50 and 75:25) formulated, were spherical with mean size of 304.5±80.8 and 733.4±101.3 nm (uncoated) and 303.8±67.2 and 494.3±71.8 nm (coated) for PLGA(50:50) and PLGA(75:25) respectively. Encapsulation efficiency (EE) and In-vitro release kinetics for uncoated and coated NPs of PLGA (50:50 & 75:25) were assessed and compared. Mean EE was 77.375±4.98% & 67.885±5.12% (uncoated) and 65.385±5.67% & 58.495±5.35% (coated). NPs showed initial burst release between 16.64-21.65% with total 42.83-44.79% over 21 days. The release increased with coating to 20.4-23.95% initially and 60.97-69.12% over 21 days. In-vivo studies were done in rats injected with (177)Lu-DOTATATE and (177)Lu-DOTATATE-NP (uncoated and PEG-coated) by imaging and organ counting after sacrificing rats at different time points over 24 hr post-injection. With (177)Lu-DOTATATE, renal uptake of 37.89±10.2%ID/g was observed, which reduced to 4.6±1.97% and 5.27±1.66%ID/g with uncoated and coated (177)Lu-DOTATATE-NP. The high liver uptake with uncoated (177)Lu-DOTATATE-NP (13.68±3.08% ID/g), reduced to 7.20±2.04%ID/g (p = 0.02) with PEG coating. PLGA NPs were easily formulated and modified for desired release properties. PLGA 50:50 NPs were a more suitable delivery vehicle for (177)Lu-DOTATATE than PLGA 75:25 because of higher EE and slower release rate. Reduced renal retention of (177)Lu-DOTATATE and reduced opsonisation strongly advocate the potential of (177)Lu-DOTATATE-PLGA-PEG NPs to reduce radiation dose in PRRT. Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a nanocarrier to deliver PRRT drugs specifically to the tumor can reduce the associated nephrotoxicity. Based on this, (177)Lu-DOTATATE loaded PLGA nanoparticles (NPs) were formulated in the present study, as a potential therapeutic model for NETs.BACKGROUNDPeptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a nanocarrier to deliver PRRT drugs specifically to the tumor can reduce the associated nephrotoxicity. Based on this, (177)Lu-DOTATATE loaded PLGA nanoparticles (NPs) were formulated in the present study, as a potential therapeutic model for NETs.DOTATATE was labeled with Lutetium-177 ((177)Lu) (labeling efficiency 98%; R(f)∼0.8). Polyethylene Glycol (PEG) coated (177)Lu-DOTATATE-PLGA NPs (50:50 and 75:25) formulated, were spherical with mean size of 304.5±80.8 and 733.4±101.3 nm (uncoated) and 303.8±67.2 and 494.3±71.8 nm (coated) for PLGA(50:50) and PLGA(75:25) respectively. Encapsulation efficiency (EE) and In-vitro release kinetics for uncoated and coated NPs of PLGA (50:50 & 75:25) were assessed and compared. Mean EE was 77.375±4.98% & 67.885±5.12% (uncoated) and 65.385±5.67% & 58.495±5.35% (coated). NPs showed initial burst release between 16.64-21.65% with total 42.83-44.79% over 21 days. The release increased with coating to 20.4-23.95% initially and 60.97-69.12% over 21 days. In-vivo studies were done in rats injected with (177)Lu-DOTATATE and (177)Lu-DOTATATE-NP (uncoated and PEG-coated) by imaging and organ counting after sacrificing rats at different time points over 24 hr post-injection. With (177)Lu-DOTATATE, renal uptake of 37.89±10.2%ID/g was observed, which reduced to 4.6±1.97% and 5.27±1.66%ID/g with uncoated and coated (177)Lu-DOTATATE-NP. The high liver uptake with uncoated (177)Lu-DOTATATE-NP (13.68±3.08% ID/g), reduced to 7.20±2.04%ID/g (p = 0.02) with PEG coating.METHODOLOGY AND FINDINGSDOTATATE was labeled with Lutetium-177 ((177)Lu) (labeling efficiency 98%; R(f)∼0.8). Polyethylene Glycol (PEG) coated (177)Lu-DOTATATE-PLGA NPs (50:50 and 75:25) formulated, were spherical with mean size of 304.5±80.8 and 733.4±101.3 nm (uncoated) and 303.8±67.2 and 494.3±71.8 nm (coated) for PLGA(50:50) and PLGA(75:25) respectively. Encapsulation efficiency (EE) and In-vitro release kinetics for uncoated and coated NPs of PLGA (50:50 & 75:25) were assessed and compared. Mean EE was 77.375±4.98% & 67.885±5.12% (uncoated) and 65.385±5.67% & 58.495±5.35% (coated). NPs showed initial burst release between 16.64-21.65% with total 42.83-44.79% over 21 days. The release increased with coating to 20.4-23.95% initially and 60.97-69.12% over 21 days. In-vivo studies were done in rats injected with (177)Lu-DOTATATE and (177)Lu-DOTATATE-NP (uncoated and PEG-coated) by imaging and organ counting after sacrificing rats at different time points over 24 hr post-injection. With (177)Lu-DOTATATE, renal uptake of 37.89±10.2%ID/g was observed, which reduced to 4.6±1.97% and 5.27±1.66%ID/g with uncoated and coated (177)Lu-DOTATATE-NP. The high liver uptake with uncoated (177)Lu-DOTATATE-NP (13.68±3.08% ID/g), reduced to 7.20±2.04%ID/g (p = 0.02) with PEG coating.PLGA NPs were easily formulated and modified for desired release properties. PLGA 50:50 NPs were a more suitable delivery vehicle for (177)Lu-DOTATATE than PLGA 75:25 because of higher EE and slower release rate. Reduced renal retention of (177)Lu-DOTATATE and reduced opsonisation strongly advocate the potential of (177)Lu-DOTATATE-PLGA-PEG NPs to reduce radiation dose in PRRT.CONCLUSIONPLGA NPs were easily formulated and modified for desired release properties. PLGA 50:50 NPs were a more suitable delivery vehicle for (177)Lu-DOTATATE than PLGA 75:25 because of higher EE and slower release rate. Reduced renal retention of (177)Lu-DOTATATE and reduced opsonisation strongly advocate the potential of (177)Lu-DOTATATE-PLGA-PEG NPs to reduce radiation dose in PRRT. Background Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a nanocarrier to deliver PRRT drugs specifically to the tumor can reduce the associated nephrotoxicity. Based on this, .sup.177 Lu-DOTATATE loaded PLGA nanoparticles (NPs) were formulated in the present study, as a potential therapeutic model for NETs. Methodology and Findings DOTATATE was labeled with Lutetium-177 (.sup.177 Lu) (labeling efficiency 98%; R.sub.f ~0.8). Polyethylene Glycol (PEG) coated .sup.177 Lu-DOTATATE-PLGA NPs (50:50 and 75:25) formulated, were spherical with mean size of 304.5±80.8 and 733.4±101.3 nm (uncoated) and 303.8±67.2 and 494.3±71.8 nm (coated) for PLGA(50:50) and PLGA(75:25) respectively. Encapsulation efficiency (EE) and In-vitro release kinetics for uncoated and coated NPs of PLGA (50:50 & 75:25) were assessed and compared. Mean EE was 77.375±4.98% & 67.885±5.12% (uncoated) and 65.385±5.67% & 58.495±5.35% (coated). NPs showed initial burst release between 16.64-21.65% with total 42.83-44.79% over 21days. The release increased with coating to 20.4-23.95% initially and 60.97-69.12% over 21days. In-vivo studies were done in rats injected with .sup.177 Lu-DOTATATE and .sup.177 Lu-DOTATATE-NP (uncoated and PEG-coated) by imaging and organ counting after sacrificing rats at different time points over 24 hr post-injection. With .sup.177 Lu-DOTATATE, renal uptake of 37.89±10.2%ID/g was observed, which reduced to 4.6±1.97% and 5.27±1.66%ID/g with uncoated and coated .sup.177 Lu-DOTATATE-NP. The high liver uptake with uncoated .sup.177 Lu-DOTATATE-NP (13.68±3.08% ID/g), reduced to 7.20±2.04%ID/g (p = 0.02) with PEG coating. Conclusion PLGA NPs were easily formulated and modified for desired release properties. PLGA 50:50 NPs were a more suitable delivery vehicle for .sup.177 Lu-DOTATATE than PLGA 75:25 because of higher EE and slower release rate. Reduced renal retention of .sup.177 Lu-DOTATATE and reduced opsonisation strongly advocate the potential of .sup.177 Lu-DOTATATE-PLGA-PEG NPs to reduce radiation dose in PRRT. BACKGROUND:Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a nanocarrier to deliver PRRT drugs specifically to the tumor can reduce the associated nephrotoxicity. Based on this, (177)Lu-DOTATATE loaded PLGA nanoparticles (NPs) were formulated in the present study, as a potential therapeutic model for NETs. METHODOLOGY AND FINDINGS:DOTATATE was labeled with Lutetium-177 ((177)Lu) (labeling efficiency 98%; R(f)∼0.8). Polyethylene Glycol (PEG) coated (177)Lu-DOTATATE-PLGA NPs (50:50 and 75:25) formulated, were spherical with mean size of 304.5±80.8 and 733.4±101.3 nm (uncoated) and 303.8±67.2 and 494.3±71.8 nm (coated) for PLGA(50:50) and PLGA(75:25) respectively. Encapsulation efficiency (EE) and In-vitro release kinetics for uncoated and coated NPs of PLGA (50:50 & 75:25) were assessed and compared. Mean EE was 77.375±4.98% & 67.885±5.12% (uncoated) and 65.385±5.67% & 58.495±5.35% (coated). NPs showed initial burst release between 16.64-21.65% with total 42.83-44.79% over 21 days. The release increased with coating to 20.4-23.95% initially and 60.97-69.12% over 21 days. In-vivo studies were done in rats injected with (177)Lu-DOTATATE and (177)Lu-DOTATATE-NP (uncoated and PEG-coated) by imaging and organ counting after sacrificing rats at different time points over 24 hr post-injection. With (177)Lu-DOTATATE, renal uptake of 37.89±10.2%ID/g was observed, which reduced to 4.6±1.97% and 5.27±1.66%ID/g with uncoated and coated (177)Lu-DOTATATE-NP. The high liver uptake with uncoated (177)Lu-DOTATATE-NP (13.68±3.08% ID/g), reduced to 7.20±2.04%ID/g (p = 0.02) with PEG coating. CONCLUSION:PLGA NPs were easily formulated and modified for desired release properties. PLGA 50:50 NPs were a more suitable delivery vehicle for (177)Lu-DOTATATE than PLGA 75:25 because of higher EE and slower release rate. Reduced renal retention of (177)Lu-DOTATATE and reduced opsonisation strongly advocate the potential of (177)Lu-DOTATATE-PLGA-PEG NPs to reduce radiation dose in PRRT. Background Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a nanocarrier to deliver PRRT drugs specifically to the tumor can reduce the associated nephrotoxicity. Based on this, 177Lu-DOTATATE loaded PLGA nanoparticles (NPs) were formulated in the present study, as a potential therapeutic model for NETs. Methodology and Findings DOTATATE was labeled with Lutetium-177 (177Lu) (labeling efficiency 98%; Rf∼0.8). Polyethylene Glycol (PEG) coated 177Lu-DOTATATE-PLGA NPs (50∶50 and 75∶25) formulated, were spherical with mean size of 304.5±80.8 and 733.4±101.3 nm (uncoated) and 303.8±67.2 and 494.3±71.8 nm (coated) for PLGA(50∶50) and PLGA(75∶25) respectively. Encapsulation efficiency (EE) and In-vitro release kinetics for uncoated and coated NPs of PLGA (50∶50 & 75∶25) were assessed and compared. Mean EE was 77.375±4.98% & 67.885±5.12% (uncoated) and 65.385±5.67% & 58.495±5.35% (coated). NPs showed initial burst release between 16.64–21.65% with total 42.83–44.79% over 21days. The release increased with coating to 20.4–23.95% initially and 60.97–69.12% over 21days. In-vivo studies were done in rats injected with 177Lu-DOTATATE and 177Lu-DOTATATE-NP (uncoated and PEG-coated) by imaging and organ counting after sacrificing rats at different time points over 24 hr post-injection. With 177Lu-DOTATATE, renal uptake of 37.89±10.2%ID/g was observed, which reduced to 4.6±1.97% and 5.27±1.66%ID/g with uncoated and coated 177Lu-DOTATATE-NP. The high liver uptake with uncoated 177Lu-DOTATATE-NP (13.68±3.08% ID/g), reduced to 7.20±2.04%ID/g (p = 0.02) with PEG coating. Conclusion PLGA NPs were easily formulated and modified for desired release properties. PLGA 50∶50 NPs were a more suitable delivery vehicle for 177Lu-DOTATATE than PLGA 75∶25 because of higher EE and slower release rate. Reduced renal retention of 177Lu-DOTATATE and reduced opsonisation strongly advocate the potential of 177Lu-DOTATATE-PLGA-PEG NPs to reduce radiation dose in PRRT. Background Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors (SSTRs) on NETs. It is, however, limited by high uptake and retention of radiolabeled peptide in kidneys resulting in unnecessary radiation exposure thus causing nephrotoxicity. Employing a nanocarrier to deliver PRRT drugs specifically to the tumor can reduce the associated nephrotoxicity. Based on this, 177Lu-DOTATATE loaded PLGA nanoparticles (NPs) were formulated in the present study, as a potential therapeutic model for NETs. Methodology and Findings DOTATATE was labeled with Lutetium-177 (177Lu) (labeling efficiency 98%; Rf∼0.8). Polyethylene Glycol (PEG) coated 177Lu-DOTATATE-PLGA NPs (50∶50 and 75∶25) formulated, were spherical with mean size of 304.5±80.8 and 733.4±101.3 nm (uncoated) and 303.8±67.2 and 494.3±71.8 nm (coated) for PLGA(50∶50) and PLGA(75∶25) respectively. Encapsulation efficiency (EE) and In-vitro release kinetics for uncoated and coated NPs of PLGA (50∶50 & 75∶25) were assessed and compared. Mean EE was 77.375±4.98% & 67.885±5.12% (uncoated) and 65.385±5.67% & 58.495±5.35% (coated). NPs showed initial burst release between 16.64–21.65% with total 42.83–44.79% over 21days. The release increased with coating to 20.4–23.95% initially and 60.97–69.12% over 21days. In-vivo studies were done in rats injected with 177Lu-DOTATATE and 177Lu-DOTATATE-NP (uncoated and PEG-coated) by imaging and organ counting after sacrificing rats at different time points over 24 hr post-injection. With 177Lu-DOTATATE, renal uptake of 37.89±10.2%ID/g was observed, which reduced to 4.6±1.97% and 5.27±1.66%ID/g with uncoated and coated 177Lu-DOTATATE-NP. The high liver uptake with uncoated 177Lu-DOTATATE-NP (13.68±3.08% ID/g), reduced to 7.20±2.04%ID/g (p = 0.02) with PEG coating. Conclusion PLGA NPs were easily formulated and modified for desired release properties. PLGA 50∶50 NPs were a more suitable delivery vehicle for 177Lu-DOTATATE than PLGA 75∶25 because of higher EE and slower release rate. Reduced renal retention of 177Lu-DOTATATE and reduced opsonisation strongly advocate the potential of 177Lu-DOTATATE-PLGA-PEG NPs to reduce radiation dose in PRRT. |
| Audience | Academic |
| Author | Shukla, Jaya Bandopadhyaya, Gurupad Arora, Geetanjali Ghosh, Sourabh Malhotra, Arun Maulik, Subir Kumar |
| AuthorAffiliation | University of Helsinki, Finland 4 Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India 3 Department of Textile Technology, Indian Institute of Technology, New Delhi, India 1 Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India 2 Department of Nuclear Medicine, Post-Graduate Institute of Medical Education and Research, Chandigarh, India |
| AuthorAffiliation_xml | – name: 1 Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India – name: 3 Department of Textile Technology, Indian Institute of Technology, New Delhi, India – name: University of Helsinki, Finland – name: 4 Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India – name: 2 Department of Nuclear Medicine, Post-Graduate Institute of Medical Education and Research, Chandigarh, India |
| Author_xml | – sequence: 1 givenname: Geetanjali surname: Arora fullname: Arora, Geetanjali – sequence: 2 givenname: Jaya surname: Shukla fullname: Shukla, Jaya – sequence: 3 givenname: Sourabh surname: Ghosh fullname: Ghosh, Sourabh – sequence: 4 givenname: Subir Kumar surname: Maulik fullname: Maulik, Subir Kumar – sequence: 5 givenname: Arun surname: Malhotra fullname: Malhotra, Arun – sequence: 6 givenname: Gurupad surname: Bandopadhyaya fullname: Bandopadhyaya, Gurupad |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22442740$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk99u0zAUxiM0xP7AGyCINAnERYudOHG8C6RqwKhUbVMZ3Fqufdx6SuNgJ4M9Bm-M06aomSaEchHr8-98x-fonOPooLIVRNFLjMY4pfj9rW1dJcpxHeQxQilBmD2JjjBLk1GeoPRg73wYHXt_i1CWFnn-LDpMEkISStBR9Pt6djGJL0Vla-EaI0vwsbYuvoa6MQriOchwCsJcKGOrVpaderMCJ-r72Or4ElpnoVJWOlOFm3ZtnT-Lg6e9gzKe1LWzQq7ixv4UTvlgqFrZBKsueA6hgo212EgfrYfn0VMtSg8v-v9J9O3zp5vzL6PZ1cX0fDIbyZzhZgRZQXJCsoXWTCApMqpCcZALxlBGEiRBJUJTAijHhFCNSSAWTFGqFE4RTU-i11vfurSe9930HKehNyljKQrEdEsoK2557cxauHtuheEbwbol73vGUaEXDGgmJVuQFCcLCojmGjJdoCyjWfD60GdrF2tQEqrGiXJgOrypzIov7R1Pw1spLYLB297A2R8t-IavjZdQlqIC23rOSFGwjCVdqtMH5OPF9dRShPebStuQVnaefEIoRXmGcOc1foQKn4K1kWHytAn6IODdICAwDfxqlqL1nk-_zv-fvfo-ZN_ssSsQZbPytmy7sfFD8NV-o_92eDfyATjbAtJZ7x1oLk2zGb9Qmik5Rrzbr13TeLdfvN-vEEweBO_8_xn2B22WKb8 |
| CitedBy_id | crossref_primary_10_1002_ppsc_201200125 crossref_primary_10_1016_j_impact_2016_12_002 crossref_primary_10_1002_smll_202200673 crossref_primary_10_1016_j_ccr_2017_01_010 crossref_primary_10_1021_acs_molpharmaceut_2c00583 crossref_primary_10_21467_anr_1_1_38_55 crossref_primary_10_1002_adma_202301698 crossref_primary_10_1002_adhm_201500177 crossref_primary_10_1039_D0CS00384K crossref_primary_10_1021_acsanm_0c02350 crossref_primary_10_2174_0929867329666220420131836 crossref_primary_10_1007_s12149_016_1067_x crossref_primary_10_1021_acs_jmedchem_3c00223 crossref_primary_10_1166_jbn_2022_3434 crossref_primary_10_1007_s12149_018_1235_2 crossref_primary_10_1053_j_seminoncol_2012_11_006 crossref_primary_10_1002_smll_201700640 crossref_primary_10_1016_j_nucmedbio_2021_06_006 crossref_primary_10_1016_j_nano_2014_12_010 crossref_primary_10_1016_j_addr_2014_07_001 crossref_primary_10_1021_acsbiomaterials_0c01226 crossref_primary_10_1016_j_lfs_2020_118206 crossref_primary_10_31083_j_ceog5105118 crossref_primary_10_1007_s40846_022_00715_6 crossref_primary_10_1002_adhm_201800558 crossref_primary_10_1007_s13346_023_01291_1 crossref_primary_10_1186_s12951_024_02520_6 |
| Cites_doi | 10.1016/j.nano.2009.02.002 10.1109/ISIEA.2009.5356377 10.1158/1078-0432.CCR-07-4149 10.1155/2010/953537 10.1016/j.ijpharm.2007.11.030 10.1016/j.ijpharm.2005.01.042 10.1002/jps.20094 10.1016/j.ijpharm.2006.11.061 10.1016/S0168-3659(01)00218-8 10.1080/10611860400013451 10.1089/cbr.2010.0881 10.1016/S0168-3659(98)00116-3 10.1016/j.ijpharm.2006.10.036 10.2967/jnumed.110.075101 10.1081/DDC-100102197 10.1016/S0168-3659(98)00185-0 10.1002/adma.200701975 10.4103/0973-8398.59948 10.1007/s11095-008-9763-4 10.2174/1874471010801010030 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2012 Public Library of Science 2012 Arora et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Arora et al. 2012 |
| Copyright_xml | – notice: COPYRIGHT 2012 Public Library of Science – notice: 2012 Arora et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Arora et al. 2012 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QO 7RV 7SN 7SS 7T5 7TG 7TM 7U9 7X2 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FG 8FH 8FI 8FJ 8FK ABJCF ABUWG AEUYN AFKRA ARAPS ATCPS AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU D1I DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB. KB0 KL. L6V LK8 M0K M0S M1P M7N M7P M7S NAPCQ P5Z P62 P64 PATMY PDBOC PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PTHSS PYCSY RC3 7X8 5PM DOA |
| DOI | 10.1371/journal.pone.0034019 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Nursing & Allied Health Database Ecology Abstracts Entomology Abstracts (Full archive) Immunology Abstracts Meteorological & Geoastrophysical Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Agricultural Science Collection Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Materials Science & Engineering Collection ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland Advanced Technologies & Aerospace Collection Agricultural & Environmental Science Collection ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection (via ProQuest SciTech Premium Collection) Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Materials Science Collection ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection (via ProQuest) ProQuest Health & Medical Complete (Alumni) Materials Science Database Nursing & Allied Health Database (Alumni Edition) Meteorological & Geoastrophysical Abstracts - Academic ProQuest Engineering Collection ProQuest Biological Science Collection Agricultural Science Database ProQuest Health & Medical Collection Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Nursing & Allied Health Premium Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection Biotechnology and BioEngineering Abstracts Environmental Science Database Materials Science Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Engineering Collection Environmental Science Collection Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Agricultural Science Database Publicly Available Content Database ProQuest Central Student ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Meteorological & Geoastrophysical Abstracts Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Advanced Technologies & Aerospace Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Agricultural Science Collection ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Ecology Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Environmental Science Collection Entomology Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Environmental Science Database ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic Meteorological & Geoastrophysical Abstracts - Academic ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) Materials Science Collection ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Agricultural & Environmental Science Collection AIDS and Cancer Research Abstracts Materials Science Database ProQuest Materials Science Collection ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection Advanced Technologies & Aerospace Database ProQuest Medical Library Animal Behavior Abstracts Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Agricultural Science Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) Medicine Chemistry Biology |
| DocumentTitleAlternate | PLGA Nanoparticles for PRRT |
| EISSN | 1932-6203 |
| ExternalDocumentID | 1324439930 oai_doaj_org_article_08fb9e75cc9b4312b7e076fe5f805575 PMC3307778 2938697441 A477065015 22442740 10_1371_journal_pone_0034019 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | India |
| GeographicLocations_xml | – name: India |
| GroupedDBID | --- 123 29O 2WC 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ AAUCC AAWOE AAYXX ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CITATION CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IGS IHR IHW INH INR IOV IPNFZ IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 OVT P2P P62 PATMY PDBOC PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS PYCSY RIG RNS RPM SV3 TR2 UKHRP WOQ WOW ~02 ~KM 3V. BBORY CGR CUY CVF ECM EIF NPM PV9 RZL PMFND 7QG 7QL 7QO 7SN 7SS 7T5 7TG 7TM 7U9 7XB 8FD 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. KL. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS RC3 7X8 5PM PUEGO AAPBV ABPTK N95 |
| ID | FETCH-LOGICAL-c691t-e5846445bff9a0ca57d386e6a9905420ced2af74e061447f1457db9d77dd13073 |
| IEDL.DBID | M48 |
| ISSN | 1932-6203 |
| IngestDate | Sun Feb 05 03:13:50 EST 2023 Wed Aug 27 01:28:55 EDT 2025 Thu Aug 21 17:42:16 EDT 2025 Thu Jul 10 23:57:40 EDT 2025 Fri Jul 25 10:39:54 EDT 2025 Tue Jun 17 22:04:35 EDT 2025 Tue Jun 10 21:01:43 EDT 2025 Fri Jun 27 05:47:31 EDT 2025 Fri Jun 27 06:06:43 EDT 2025 Thu May 22 21:23:42 EDT 2025 Wed Feb 19 02:42:18 EST 2025 Tue Jul 01 00:46:24 EDT 2025 Thu Apr 24 23:03:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. Creative Commons Attribution License |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c691t-e5846445bff9a0ca57d386e6a9905420ced2af74e061447f1457db9d77dd13073 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Conceived and designed the experiments: GB JS SG. Performed the experiments: GA. Analyzed the data: GA JS. Contributed reagents/materials/analysis tools: GB AM SKM. Wrote the paper: GA SG. |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1371/journal.pone.0034019 |
| PMID | 22442740 |
| PQID | 1324439930 |
| PQPubID | 1436336 |
| PageCount | e34019 |
| ParticipantIDs | plos_journals_1324439930 doaj_primary_oai_doaj_org_article_08fb9e75cc9b4312b7e076fe5f805575 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3307778 proquest_miscellaneous_948895925 proquest_journals_1324439930 gale_infotracmisc_A477065015 gale_infotracacademiconefile_A477065015 gale_incontextgauss_ISR_A477065015 gale_incontextgauss_IOV_A477065015 gale_healthsolutions_A477065015 pubmed_primary_22442740 crossref_citationtrail_10_1371_journal_pone_0034019 crossref_primary_10_1371_journal_pone_0034019 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2012-03-19 |
| PublicationDateYYYYMMDD | 2012-03-19 |
| PublicationDate_xml | – month: 03 year: 2012 text: 2012-03-19 day: 19 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: San Francisco – name: San Francisco, USA |
| PublicationTitle | PloS one |
| PublicationTitleAlternate | PLoS One |
| PublicationYear | 2012 |
| Publisher | Public Library of Science Public Library of Science (PLoS) |
| Publisher_xml | – name: Public Library of Science – name: Public Library of Science (PLoS) |
| References | DR Kalaria (ref14) 2009; 26 Sinjan De (ref20) 2004; 5 Kalevi Kairemo (ref5) 2008; 1 Thirumala Govender (ref25) 1999; 57 Tapas Das (ref7) 2011; 26 S Dadashzadeh (ref17) 2008; 353 KevinJ Harrington (ref10) 2001; 7 Giovanni Paganelli (ref1) 2007 ref19 Yan Wu (ref30) 2005; 295 Avinash Budhian (ref13) 2007; 336 Goldie Kaul (ref33) 2004; 12 J Panyam (ref26) 2004; 93 Seung Chan Lee (ref16) 1999; 59 Ganesan Vaidyanathan (ref28) 2003; 9 Raffaella Rossin (ref32) 2005; 46 K Nakano (ref21) 2007; 2 VJ Mohanraj (ref9) 2006; 5 Waree Tiyaboonchai (ref22) 2003; 11 SallyJ DeNardo (ref31) 2007; 48 G Gnanasegaran (ref3) 2005; 20 SeanX Wang (ref11) 2008; 14 Shirui Mao (ref23) 2007; 334 Jaya Shukla (ref8) 2007; 10 Gann Ting (ref6) 2010; 2010 Jose Mario Barichello (ref24) 1999; 25 Jin Xie (ref34) 2007; 19 MS Muthu (ref12) 2009; 3 J Sameni (ref15) 2009 (ref4) 2006 Erik Vegt (ref2) 2010; 51 Jason Park (ref18) 2009; 5 (ref27) 2010 Ya-Ping Li (ref29) 2001; 71 11234875 - Clin Cancer Res. 2001 Feb;7(2):243-54 17207944 - Int J Pharm. 2007 May 24;336(2):367-75 19341815 - Nanomedicine. 2009 Dec;5(4):410-8 18191511 - Int J Pharm. 2008 Apr 2;353(1-2):251-9 15621684 - J Drug Target. 2004;12(9-10):585-91 21728843 - Cancer Biother Radiopharm. 2011 Jun;26(3):395-400 17450243 - Hell J Nucl Med. 2007 Jan-Apr;10(1):9-13 11274752 - J Control Release. 2001 Apr 2;71(2):203-11 15176068 - J Pharm Sci. 2004 Jul;93(7):1804-14 10332048 - J Control Release. 1999 May 20;59(2):123-32 15760050 - AAPS PharmSciTech. 2004;5(4):e53 15848008 - Int J Pharm. 2005 May 13;295(1-2):235-45 18998202 - Pharm Res. 2009 Mar;26(3):492-501 12738745 - Clin Cancer Res. 2003 May;9(5):1868-76 17196348 - Int J Pharm. 2007 Apr 4;334(1-2):137-48 18559620 - Clin Cancer Res. 2008 Jun 15;14(12):3975-83 16000291 - J Nucl Med. 2005 Jul;46(7):1210-8 9971898 - J Control Release. 1999 Feb 1;57(2):171-85 20811605 - J Biomed Biotechnol. 2010;2010. pii: 953537. doi: 10.1155/2010/953537 10194602 - Drug Dev Ind Pharm. 1999 Apr;25(4):471-6 17332622 - J Nucl Med. 2007 Mar;48(3):437-44 20554737 - J Nucl Med. 2010 Jul;51(7):1049-58 |
| References_xml | – volume: 2 start-page: 220 year: 2007 ident: ref21 article-title: Cellular interaction of PEGylated PLGA nanospheres with macrophage J774 cells using flow cytometry. publication-title: Asian J Pharm Sci – volume: 5 start-page: Article 53 year: 2004 ident: ref20 article-title: Particle Size and Temperature Effect on the Physical Stability of PLGA Nanospheres and Microspheres Containing Bodipy. publication-title: AAPS Pharm Sci Tech – volume: 5 start-page: 410 year: 2009 ident: ref18 article-title: PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. publication-title: Nanomed Nanotech Biol Med doi: 10.1016/j.nano.2009.02.002 – volume: 48 start-page: 437 year: 2007 ident: ref31 article-title: Thermal Dosimetry Predictive of Efficacy of 111In-ChL6 Nanoparticle AMF–Induced Thermoablative Therapy for Human Breast Cancer in Mice. publication-title: J Nucl Med – year: 2009 ident: ref15 article-title: The Effect of Preparation Parameters on the Size and Morphology of PLGA-Based Nanoparticle. doi: 10.1109/ISIEA.2009.5356377 – ident: ref19 article-title: Coating layered nanoparticles alters immune cell uptake. – volume: 14 start-page: 3975 year: 2008 ident: ref11 article-title: Intraoperative 186Re-liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model. publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-07-4149 – volume: 2010 start-page: 1 year: 2010 ident: ref6 article-title: Nanotargeted Radionuclides for Cancer Nuclear Imaging and Internal Radiotherapy. publication-title: J Biomed Biotechnol doi: 10.1155/2010/953537 – volume: 353 start-page: 251 year: 2008 ident: ref17 article-title: The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. publication-title: Intl J Pharm doi: 10.1016/j.ijpharm.2007.11.030 – volume: 295 start-page: 235 year: 2005 ident: ref30 article-title: Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2005.01.042 – volume: 9 start-page: 1868 year: 2003 ident: ref28 article-title: Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. publication-title: Clin Can Res – volume: 46 start-page: 1210 year: 2005 ident: ref32 article-title: 64Cu-Labeled Folate-Conjugated Shell Cross- Linked Nanoparticles for Tumor Imaging and Radiotherapy: Synthesis, Radiolabeling, and Biologic Evaluation. publication-title: J Nucl Med – volume: 20 start-page: 55 year: 2005 ident: ref3 article-title: Recent Trends in Radionuclide Imaging and Targeted Radionuclide Therapy of Neuroendocrine Tumors. publication-title: Indian J Nucl Med – volume: 93 start-page: 1804 year: 2004 ident: ref26 article-title: Solid-state solubility influences encapsulation and release of hydrophobic drugs from PLGA/PLA nanoparticles. publication-title: J Pharm Sci doi: 10.1002/jps.20094 – volume: 336 start-page: 367 year: 2007 ident: ref13 article-title: Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2006.11.061 – volume: 10 start-page: 9 year: 2007 ident: ref8 article-title: Morphology Based Release Kinetics of 99mTc(V) DMSA Loaded PLGA Microspheres as Targeted Radiotherapeutic Model. publication-title: Hell J Nucl Med – year: 2007 ident: ref1 article-title: Neuroendocrine Tumors. – volume: 11 start-page: 51 year: 2003 ident: ref22 article-title: Chitosan Nanoparticles: A Promising System for Drug Delivery. publication-title: Naresuan University Journal – volume: 71 start-page: 203 year: 2001 ident: ref29 article-title: PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. publication-title: J Control Release doi: 10.1016/S0168-3659(01)00218-8 – volume: 12 start-page: 585 year: 2004 ident: ref33 article-title: Biodistribution and targeting potential of poly (ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. publication-title: J Drug Target doi: 10.1080/10611860400013451 – volume: 26 start-page: 395 year: 2011 ident: ref7 article-title: Preparation of Patient Doses of 177Lu-DOTA-TATE Using Indigenously Produced 177Lu: The Indian Experience. publication-title: Cancer Biother Radiopharm doi: 10.1089/cbr.2010.0881 – volume: 7 start-page: 243 year: 2001 ident: ref10 article-title: Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. publication-title: Clin Cancer Res – volume: 57 start-page: 171 year: 1999 ident: ref25 article-title: PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. publication-title: J Control Release doi: 10.1016/S0168-3659(98)00116-3 – volume: 334 start-page: 137 year: 2007 ident: ref23 article-title: Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. publication-title: Int J Pharm doi: 10.1016/j.ijpharm.2006.10.036 – volume: 51 start-page: 1049 year: 2010 ident: ref2 article-title: Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. publication-title: J Nucl Med doi: 10.2967/jnumed.110.075101 – volume: 25 start-page: 471 year: 1999 ident: ref24 article-title: Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. publication-title: Drug Dev Ind Pharm doi: 10.1081/DDC-100102197 – volume: 59 start-page: 123 year: 1999 ident: ref16 article-title: Quantitative analysis of polyvinyl alcohol on the surface of poly(D,L-lactide-co-glycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration. publication-title: J control Release doi: 10.1016/S0168-3659(98)00185-0 – year: 2010 ident: ref27 – volume: 19 start-page: 3163 year: 2007 ident: ref34 article-title: Controlled PEGylation of Monodisperse Fe3O4 Nanoparticles for Reduced Non-Specific Uptake by Macrophage Cells. publication-title: Adv Mater doi: 10.1002/adma.200701975 – volume: 5 start-page: 561 year: 2006 ident: ref9 article-title: Nanoparticles – A Review. publication-title: Trop J Pharm Res – volume: 3 start-page: 266 year: 2009 ident: ref12 article-title: Nanoparticles based on PLGA and its copolymer: An overview. publication-title: Asian J Pharm doi: 10.4103/0973-8398.59948 – volume: 26 start-page: 492 year: 2009 ident: ref14 article-title: Design of biodegradable nanoparticles for oral delivery of Doxorubicin: In vivo pharmacokinetics and toxicity studies in rats. publication-title: Pharm res doi: 10.1007/s11095-008-9763-4 – volume: 1 start-page: 30 year: 2008 ident: ref5 article-title: Nanoparticles in Cancer. publication-title: Curr Radiopharm doi: 10.2174/1874471010801010030 – year: 2006 ident: ref4 article-title: Somatostatin and the Somatostatin Receptors: Versatile Regulators of Biological Activity. – reference: 21728843 - Cancer Biother Radiopharm. 2011 Jun;26(3):395-400 – reference: 10194602 - Drug Dev Ind Pharm. 1999 Apr;25(4):471-6 – reference: 20811605 - J Biomed Biotechnol. 2010;2010. pii: 953537. doi: 10.1155/2010/953537 – reference: 11274752 - J Control Release. 2001 Apr 2;71(2):203-11 – reference: 20554737 - J Nucl Med. 2010 Jul;51(7):1049-58 – reference: 18559620 - Clin Cancer Res. 2008 Jun 15;14(12):3975-83 – reference: 15176068 - J Pharm Sci. 2004 Jul;93(7):1804-14 – reference: 15621684 - J Drug Target. 2004;12(9-10):585-91 – reference: 9971898 - J Control Release. 1999 Feb 1;57(2):171-85 – reference: 18191511 - Int J Pharm. 2008 Apr 2;353(1-2):251-9 – reference: 18998202 - Pharm Res. 2009 Mar;26(3):492-501 – reference: 15760050 - AAPS PharmSciTech. 2004;5(4):e53 – reference: 17332622 - J Nucl Med. 2007 Mar;48(3):437-44 – reference: 17450243 - Hell J Nucl Med. 2007 Jan-Apr;10(1):9-13 – reference: 15848008 - Int J Pharm. 2005 May 13;295(1-2):235-45 – reference: 10332048 - J Control Release. 1999 May 20;59(2):123-32 – reference: 16000291 - J Nucl Med. 2005 Jul;46(7):1210-8 – reference: 11234875 - Clin Cancer Res. 2001 Feb;7(2):243-54 – reference: 19341815 - Nanomedicine. 2009 Dec;5(4):410-8 – reference: 17207944 - Int J Pharm. 2007 May 24;336(2):367-75 – reference: 12738745 - Clin Cancer Res. 2003 May;9(5):1868-76 – reference: 17196348 - Int J Pharm. 2007 Apr 4;334(1-2):137-48 |
| SSID | ssj0053866 |
| Score | 2.1947677 |
| Snippet | Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin Receptors... Background Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin... BACKGROUND:Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin... Background Peptide receptor radionuclide therapy (PRRT), employed for treatment of neuroendocrine tumors (NETs) is based on over-expression of Somatostatin... |
| SourceID | plos doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e34019 |
| SubjectTerms | Acids Animals Background radiation Biology Breast cancer Cancer therapies Chemistry Coating Dosimetry Drug delivery systems Drug dosages Drugs Health aspects Kidney Kidneys Kinetics Lactic Acid - pharmacology Liver Lutetium Materials Science Medical research Medicine Nanoparticles Nanoparticles - administration & dosage Neuroendocrine tumors Neuroendocrine Tumors - radiotherapy Nuclear medicine Octreotide - analogs & derivatives Octreotide - pharmacology Organometallic Compounds - pharmacology Overexpression Peptides Polyethylene glycol Polyglycolic Acid - pharmacology Polylactide-co-glycolide Polyols Radiation Radiation Dosage Radiation effects Radiation therapy Radioisotopes Rats Rats, Wistar Receptors Receptors, Somatostatin Retention Somatostatin Somatostatin receptors Studies Therapy Tumors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELZQT1wQy2sLC1gICThkN0n9qLkVxLIgXgIW7S2yHRuQSlI1KRI_g3_MjO1GDVppOXCr7PEonRmPv1HGXwh5CBBYCKNYpgQzGfNcZMqwWWa4zo2Amih2E759J05O2eszfrbzqS_sCYv0wNFwR_ncG-UktxZ1FKWRDkpv77ifI31UYC-FM29bTMUcDLtYiHRRbiaLo-SXw1XbuEOkZAnMOjsHUeDrH7LyZLVsu_Mg59-dkztH0fFVciVhSLqIz75HLrnmGtlLu7SjjxOV9JPr5PeHNy8XtNENlMapA44CSqUr7GWpHYV0B79gYK1rcNDGLnE03sn6RVtPA92la-rW4i1B2m9-tOvuKdW0aX-6Jd0yktM-dN92oLCOdLS4eO3wMVF1cD-t287dIKfHLz4_P8nSRxgyK1TRZw4RCmPceK90bjWXNRjXCQ3HGGdlbl1dai-ZC6Wl9AUDCaNqKeu6wARyk0waMPs-oS7PteQaIoN7ZpXWgoNyAwWhnzvvzJTMth6pbGIoxw9lLKvw2k1CpRINXKEfq-THKcmGVavI0HGB_DN09iCL_NphAKKuSr6oLoq6KbmPoVLFy6pDlqgWTOJ7Y8BYU_IgSCDHRoNNPF_1puuqV--__IPQp48joUdJyLdgDqvTxQn4T8jdNZI8GElCprCj6X0M7K1VOrARgDtEqDms3Ab7-dN0mEal2JjXuHbTVQoOAMVVCcpvxa0xGBbAISslg8VytGlGlh_PNN-_BYbzGQSOlPPb_8NVd8hlALkl9g0W6oBM-vXG3QUg2Zt7IWf8AS4Ac14 priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Technology Collection dbid: 8FG link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LbxMxELYgXLggyqspBSyEBBy23d34EXNB4ZEWxKMKLeptZXvtghR2Qzbhf_CPmfE6SxdVwC2yxyNnZjyeWY8_E_IIQmAhjGKJEswkzHORKMNGieE6NQJyoraa8P0HcXjC3p7y0_jBrYlllRufGBx1WVv8Rr4PWRPD2HmUPl98T_DVKDxdjU9oXCZXMthpsKRrPD3YeGJYy0LE63Ijme1H7ewt6srtITBLwNc5tx0F1P7ONw8W87q5KPD8s37y3IY0vU6uxUiSTlrVb5FLrrpBtuJabeiTCCj99Cb5efTuYELBj0KCHOvgKMSq9AgrWkpHIXSEX9Aw0yWoaW3n2Hrc4g3Q2tOA4OEqEBLeFaTH62_1snlGgWf9w8EUIi45XYUa3AYYli0oLQ6eOZwmsg5GQF_VjbtFTqavj18eJvEphsQKla0Sh3EKY9x4r3RqNZclCNcJDZsZZ3lqXZlrL5kLCab0GQMKo0opyzJDN3KbDCoQ-zahLk215Brsg3tmldaCA3MDaaEfO-_MkIw2GilsxCnH5zLmRTh8k5CvtAIuUI9F1OOQJN2oRYvT8Q_6F6jsjhZRtkNDvTwroi6KdOyNcpJbi_ab5Ua6VArvuB8jdBkfkgdoKkV7ZbXzFcWESTw9hkhrSB4GCkTaqLCU50yvm6Z48_HzfxB9mvWIHkciX4M4rI7XJ-A_IYJXj3K3Rwn-wva6t9GwN1Jpit8rC0ZujP3ibtp1I1Msz6tcvW4KBduA4ioH5nfapdEJFkJElksGg2Vv0fQk3--pvn4JOOcjMBwpxzt_n9VdchWC2BzrAjO1Swar5drdg0BxZe4Hb_ALkVZpOg priority: 102 providerName: ProQuest |
| Title | PLGA Nanoparticles for Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Novel Approach towards Reduction of Renal Radiation Dose |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/22442740 https://www.proquest.com/docview/1324439930 https://www.proquest.com/docview/948895925 https://pubmed.ncbi.nlm.nih.gov/PMC3307778 https://doaj.org/article/08fb9e75cc9b4312b7e076fe5f805575 http://dx.doi.org/10.1371/journal.pone.0034019 |
| Volume | 7 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3fb9MwELZG98ILYvxaxygWQgIeUiWpHddICHVj3UBsTKVDfYvsxB5IJSlNi-DP4D_mznEjgobYS1TZ51NyPtvf1efPhDwFCJwkWrJAJkwHzPIkkJoNAs1VqBOIiepswtOz5OSCvZvx2RbZ3NnqDVhdGdrhfVIXy3n_x7efr2HAv3K3Noho06i_KAvTR8KVEHlAt2FtEninwSlr9hVgdLvdS0QtQRKHA3-Y7l9aWouV4_RvZu7OYl5WV8HSv7Mr_1iuxrfJLY8z6ah2jB2yZYo7ZMeP5Io-93TTL-6SX-fvj0cUZlkIn32WHAUkS88x3yU3FIAl_IKCicqhE9fZHEunNRsBLS11_B6myMsMTxLS6fpruaxeUtBZfjfwCp61nK5chm4FCvOashYbTwy-Jqp2LkLflJW5Ry7GR9PDk8Bf1BBkiYxWgUEUwxjX1koVZoqLHAxtEgVLHWdxmJk8VlYw48JPYSMGElrmQuR5hJPMfdIpwOy7hJowVIIr8B5uWSaVSjgo1xA02qGxRnfJYNMjaeZZzPEyjXnqtuYERDO1gVPsx9T3Y5cETatFzeLxH_kD7OxGFjm4XUG5vEx9X6Th0GppBM8y9O4o1sKEIrGG2yESm_EueYyuktYHWpuZJB0xgXvLgMO65ImTQB6OAhN9LtW6qtK3Hz5dQ-jjpCX0zAvZEsyRKX-4Ar4J-b1akvstSZhNslb1Ljr2xioV2AgAIKLYEFpunP3qatpUo1JM3itMua5SCYuE5DIG5Q_qodEYFgAkiwWDxqI1aFqWb9cUXz47FvQBOI4Qw71rf_lDchPQbowJhJHcJ53Vcm0eAaJc6R65IWYCnsPDCJ_j4x7ZPjg6O5_03H80PTeJ_AYqfHop |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGeYAXxPhaYTALgYCHbPnwR4OEUGF0LevGtHVobyFO7IFUktK0IP4M_hH-Ru4SJyxoAl72Vtnnk3t3Pt_F558JeQQhsBAqZE4omHKY4cIJFQscxWNXCciJqmrCvX0xPGZvT_jJCvlZ34XBssraJ5aOOs0T_Ea-BVkTw9g5cF_Ovjj4ahSertZPaFRmsau_f4OUrXgx2gb9Pvb9wZvJ66FjXxVwEhF6C0fjlssYV8aEsZvEXKZBT2gRg1_mzHcTnfqxkUyXuZI0HgMKFaZSpqmHKwL4XiKXWQA7Od5MH-zUnh98hxD2el4gvS1rDZuzPNObCART4vmc2f7KVwKavaAzm-bFeYHun_WaZzbAwXVyzUautF-Z2ipZ0dkNsmp9Q0GfWgDrZzfJj4PxTp-C34aE3NbdUYiN6QFW0KSaQqgKv6DhME7BLJbJFFsnFb4BzQ0tEUN0BkrBu4l0svycz4vnFHjmXzVMweKg00VZ81sAw7QCwcXBhxqniaxLo6PbeaFvkeMLUdJt0slA7GuEateNJY_BHrlhSRjHggNzBWmo6WmjVZcEtUaixOKi4_Mc06g87JOQH1UCjlCPkdVjlzjNqFmFC_IP-leo7IYWUb3Lhnx-GlldRG7PqFBLniS4XjxfSe1KYTQ3PYRK412ygaYSVVdkG98U9ZnE02qI7LrkYUmByB4Zlg6dxsuiiEbv3v8H0dFhi-iJJTI5iCOJ7XUN-E-IGNaiXG9Rgn9KWt1raNi1VIro90qGkbWxn99Nm25kiuWAmc6XRRTCthPy0Afmd6ql0QgWQlLmSwaDZWvRtCTf7sk-fSxx1QMwHCl7d_8-qw1yZTjZG0fj0f7uPXIVAmgfaxK9cJ10FvOlvg9B6kI9KD0DJR8u2hX9ArGzpU4 |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ZbxMxELZKkBAviHI1UKiFQMDDNnv42EVCKDSEhpYSlRT1zexhF6SwG7IJiJ_B3-HXMbPrLF1UAS99i-zxyPEcnlmPPxPyAEJgIZKIOZFgicMMF06UsMBJeOwmAnKiuprwzYHYPWKvj_nxGvm5uguDZZUrn1g56qxI8Rt5D7ImhrFz4PaMLYsYD4bPZ18cfEEKT1pXz2nUKrKnv3-D9K18NhqArB_6_vDlZGfXsS8MOKmIvIWjcftljCfGRLGbxlxmQSi0iMFHc-a7qc782Eimq7xJGo8BRRJlUmaZh9YBfC-QizKQIdpYuNOUl4AfEcJe1Quk17OasT0rcr2NoDAVts-prbB6MaDZFzqzaVGeFfT-Wbt5ajMcXiVXbBRL-7XarZM1nV8j69ZPlPSxBbN-cp38GO-_6lPw4ZCc2xo8CnEyHWM1TaYphK3wCxoO4wxUZJlOsXVSYx3QwtAKPUTnICC8p0gny8_FvHxKgWfxVcMULCY6XVT1vyUwzGpAXBx8qHGayLpSQDooSn2DHJ2LkG6STg7LvkGodt1Y8hh0kxuWRnEsODBPICU1oTY66ZJgJRGVWox0fKpjqqqDPwm5Ur3ACuWorBy7xGlGzWqMkH_Qv0BhN7SI8F01FPMTZWWh3NAkkZY8TdF2PD-R2pXCaG5ChE3jXbKFqqLq67KNn1J9JvHkGqK8LrlfUSDKR472chIvy1KN3r7_D6J3hy2iR5bIFLAcaWyvbsB_QvSwFuVmixJ8Vdrq3kDFXq1KqX5bNYxcKfvZ3bTpRqZYGpjrYlmqCLagiEc-ML9Vm0azsBCeMl8yGCxbRtNa-XZP_uljhbEegOJIGd7--6y2yCVwQmp_dLB3h1yGWNrH8kQv2iSdxXyp70K8ukjuVY6Bkg_n7Yl-AezIqU8 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PLGA+Nanoparticles+for+Peptide+Receptor+Radionuclide+Therapy+of+Neuroendocrine+Tumors%3A+A+Novel+Approach+towards+Reduction+of+Renal+Radiation+Dose&rft.jtitle=PloS+one&rft.au=Arora%2C+Geetanjali&rft.au=Shukla%2C+Jaya&rft.au=Ghosh%2C+Sourabh&rft.au=Maulik%2C+Subir+Kumar&rft.date=2012-03-19&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=7&rft.issue=3&rft.spage=e34019&rft_id=info:doi/10.1371%2Fjournal.pone.0034019&rft.externalDocID=A477065015 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |